Docetaxel, Oxaliplatin, and S-1 Chemotherapy Combination Shows Promising Results in Gastric Cancer Study

Strategic Insights -

Researchers from Hallym University in South Korea conducted a phase I study to evaluate the maximum tolerated dose (MTD), recommended dose (RD), and activity of a combined chemotherapy regimen of docetaxel, oxaliplatin, and S-1 in patients with metastatic gastric cancer. The study aimed to determine the optimal doses of each medication to achieve the best treatment outcome.

Key Takeaways:

  • The study involved nine patients with metastatic gastric cancer who were enrolled in the phase I study.
  • The researchers found that the doses of docetaxel/oxaliplatin/S-1 that caused dose-limiting toxicity (febrile neutropenia) were 52.5/80/80 mg/m(2) for level 1B and 52.5/105/80 mg/m(2) for level 1A.
  • The recommended dose (RD) of the combined regimen was determined to be docetaxel 52.5 mg/m(2) and oxaliplatin 105 mg/m(2) on day 1, and S-1 80 mg/m(2) on days 1-14 of every 21-day cycle.
  • Six partial responses were noted, and the overall response rate was 67%.
  • The study concluded that a phase II study using the recommended dose is currently underway.

Statistics:

  • 9 patients were enrolled in the phase I study.
  • 1 of 6 patients at level 1A and 2 of 3 patients at level 1B developed dose-limiting toxicity (febrile neutropenia) during the initial two cycles.
  • 6 partial responses were noted.
  • The overall response rate was 67%.
  • The study involved 6 patients assigned to level 1A and 3 patients assigned to level 1B.

Sources:

  • D.Y. Zang et al. (2009) "Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer." Cancer Chemotherapy and Pharmacology, 64(5), 877-883.
  • Hallym University, Sacred Heart Hospital, Dept. of Internal Medical, Division Hematology Oncology, 896 Pyeongchon Dong, Anyang 431070, Gyeonggi Do, South Korea.
  • Springer, 233 Spring St., New York, NY 10013, USA.